Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles

FEMS Immunology and Medical Microbiology

Volumn 52, Issue 1, 2008, Pages 99-109

  Xu, Yufei ^a,b   Zhang, Hongtao ^c   Xu, Xuemei ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

Chimeric virus like particles; Human papillomavirus; mLTK63; Vaccine

Indexed keywords

CD4 ANTIGEN; CYTOKINE; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; PROTEIN L1 L2 MODIFIED LTK63; UNCLASSIFIED DRUG; VIRUS PROTEIN; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; IMMUNOGENICITY; INSECT CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SPLEEN CELL; TH1 CELL; TH2 CELL; VIRUS INFECTION; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; BACTERIAL TOXINS; CAPSID PROTEINS; CELL LINE; CELL PROLIFERATION; CYTOKINES; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 16; INJECTIONS, INTRAMUSCULAR; LYMPHOCYTES; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; SPLEEN; VIROSOMES;

EID: 38149010588     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2007.00339.x     Document Type: Article

References (40)

1. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM Galloway DA (1996a) Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223 : 174 184.
2. Christensen ND, Reed CA, Cladel NM, Han R Kreider JW (1996b) Immunization with virus like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70 : 960 965.
3. Collier B, Oberg D, Zhao X Schwartz S (2002) Specific inactivation of inhibitory sequences in the 5′ end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells. J Virol 76 : 2739 2752.
4. de Haan L, Holtrop M, Verweij WR, Agsteribbe E Wilschut J (1996) Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: role of the A subunit. Vaccine 14 : 260 266.
5. de Haan L, Feil IK, Verweij WR, Holtrop M, Hol WG, Agsteribbe E Wilschut J (1998a) Mutational analysis of the role of ADP-ribosylation activity and GM1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin. Eur J Immunol 28 : 1243 1250.
6. de Haan L, Verweij WR, Feil IK, Holtrop M, Hol WG, Agsteribbe E Wilschut J (1998b) Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit. Immunology 94 : 424 430.
7. Di Tommaso A, Saletti G, Pizza M, Rappuoli R, Dougan G, Abrignani S, Douce G De Magistris MT (1996) Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun 64 : 974 979.
8. Dupuy C, Buzoni-Gatel D, Touze A, Le Cann P, Bout D Coursaget P (1997) Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb Pathog 22 : 219 225.
9. Gerber S, Lane C, Brown DM, Lord E, DiLorenzo M, Clements JD, Rybicki E, Williamson AL Rose RC (2001) Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol 75 : 4752 4760.
10. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM Schiller JT (1998) Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95 : 1800 1805.
11. Greer CE, Petracca R, Buonamassa DT, Di Tommaso A, Gervase B, Reeve RL, Ugozzoli M, Van Nest G, De Magistris MT Bensi G (2000) The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles. Vaccine 19 : 1008 1012.
12. Harper DM, Franco EL, Wheeler C et al 2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 : 1757 1765.
13. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA Dubin G (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 : 1247 1255.
14. Harro CD, Pang YY, Roden RB et al 2001) Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93 : 284 292.
15. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR Schiller JT (1993) Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67 : 6929 6936.
16. Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR Schiller JT (2001) Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 166 : 5346 5355.
17. Lenz P, Lowy DR Schiller JT (2005) Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur J Immunol 35 : 1548 1556.
18. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU Barr E (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 : 18 27.
19. Muller M, Zhou J, Reed TD, Rittmuller C, Burger A, Gabelsberger J, Braspenning J Gissmann L (1997) Chimeric papillomavirus-like particles. Virology 234 : 93 111.
20. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 : 518 527.
21. Parkin DM, Bray F, Ferlay J Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55 : 74 108.
22. Partidos CD, Salani BF, Pizza M Rappuoli R (1999) Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides. Immunol Lett 67 : 209 216.
23. Pinto LA, Edwards J, Castle PE et al 2003) Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 188 : 327 338.
24. Pinto LA, Castle PE, Roden RB et al 2005) HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine 23 : 3555 3564.
25. Pinto LA, Viscidi R, Harro CD et al 2006) Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 353 : 451 462.
26. Rappuoli R, Pizza M, Douce G Dougan G (1999) Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 20 : 493 500.
27. Roden RB, Hubbert NL, Kirnbauer R, Breitburd F, Lowy DR Schiller JT (1995) Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol 69 : 5147 5151.
28. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR Schiller JT (1996) Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 70 : 3298 3301.
29. Ryan EJ, McNeela E, Murphy GA, Stewart H, O'Hagan D, Pizza M, Rappuoli R Mills KH (1999) Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect Immun 67 : 6270 6280.
30. Schiller JT Nardelli-Haefliger D (2006) Second generation HPV vaccines to prevent cervical cancer. Vaccine 24 (Suppl 3) : S147 S153.
31. Shi W, Liu J, Huang Y Qiao L (2001) Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol 75 : 10139 10148.
32. Stephenson I, Zambon MC, Rudin A et al 2006) Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 80 : 4962 4970.
33. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB Schlegel R (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92 : 11553 11557.
34. Tobery TW, Smith JF, Kuklin N, Skulsky D, Ackerson C, Huang L, Chen L, Cook JC, McClements WL Jansen KU (2003) Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. Vaccine 21 : 1539 1547.
35. Xu YF, Zhang YQ, Xu XM Song GX (2006) Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes. Arch Virol 151 : 2133 2148.
36. Xu YF, Wang QY, Zhang HT, Han YH, Song GX Xu XM (2007a) Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles. Chin Med J (English) 120 : 503 508.
37. Xu Y, Wang Q, Han Y, Song G Xu X (2007b) Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles. J Med Microbiol 56 : 907 913.
38. Yang R, Murillo FM, Cui H, Blosser R, Uematsu S, Takeda K, Akira S, Viscidi RP Roden RB (2004a) Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol 78 : 11152 11160.
39. Yang R, Murillo FM, Lin KY, Yutzy WH, Uematsu S, Takeda K, Akira S, Viscidi RP Roden RB (2004b) Human papillomavirus type-16 virus-like particles activate complementary defense responses in key dendritic cell subpopulations. J Immunol 173 : 2624 2631.
40. Zinkernagel RM, Bachmann MF, Kundig TM, Oehen S, Pirchet H Hengartner H (1996) On immunological memory. Annu Rev Immunol 14 : 333 367.